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Background: Although there are more than 1000 mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene, most
of them are uncommon and only limited information exists regarding genotype–pulmonary phenotype relationships.
Methods: We determined and classified the CFTR mutations using denaturing high-performance liquid chromatography and developed new,
quantitative methods to categorize pulmonary phenotypes.
Results: Two novel alleles were discovered, namely G1047R and 1525-2AYG, which were accompanied by F508del and G551D
mutations, respectively. Assessment of numerous options revealed that CF pulmonary phenotype categorization in children cannot be
accomplished with clinical or pulmonary function data but is facilitated by longitudinal quantitative chest radiology. It was most useful to
categorize pulmonary disease status by evaluating the typical pattern of abnormalities in patients homozygous for the F508del mutation, and
then compare patients with minor mutations to this typical CF pulmonary phenotype. By this method, both patients with novel mutations
have pulmonary phenotypes typical of F508del homozygotes. However, patients with class IV mutations (e.g., R347P) or with pancreatic
sufficiency showed serial chest radiographs that were atypically mild.
Conclusions: Longitudinal quantitative chest radiography provides a new strategy for CF pulmonary phenotype categorization that should
be useful for genotype–phenotype delineation in individual patients and in both epidemiologic studies and clinical trials involving groups of
children with CF.
D 2005 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights reserved.Keywords: Cystic fibrosis; Genotype; Phenotype; Lung disease1. Introduction
Cystic fibrosis (CF) occurs due to mutations in the cystic
fibrosis transmembrane conductance regulator (CFTR)
gene, and more than 1000 mutant alleles have been
described to date [1–5]. Most of the CF mutant alleles are
rare and usually occur in compound heterozygote CF
patients who also have one of the major mutations such as
the most common mutant allele, F508del [2]. Based on a1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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types, but phenotypic categorization beyond pancreatic
functional status has been difficult [5,8,9,11]. Pancreatic
phenotype delineation has been relatively simple [5,7,11]
because dichotomous categories exist and ‘‘yes/no’’ speci-
fication can be readily applied to the question about the
presence of pancreatic insufficiency (PI). Pancreatic suffi-
ciency (PS) is a ‘‘mild’’ phenotype that occurs in about 15%
of CF patients [14–16] and can be easily distinguished from
PI. The same is obviously true for meconium ileus (MI),
which occurs in about 20% of North American CF patients
[17]. It has been shown unequivocally during the past
decade that certain mutations are associated with either PI or
PS and that patients with MI typically have PI [5,7,11].s 5 (2006) 33 – 41ed by Elsevier B.V. All rights reserved.
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II,. . .V) based on the molecular mechanisms altered due to
the mutant CFTR gene and on the genotype–pancreatic
phenotype relationship [2,19]. Sweat chloride abnormalities
also relate in part to genotype since classes IV and V are
potentially associated with relatively lower, though still
abnormal, levels [5]. On the other hand, despite numerous
attempts to identify associations between genotype and CF
pulmonary phenotype, this relationship is still not well
understood and little success has been achieved in efforts to
establish correlations [5,10,11]. Most efforts have relied on
pulmonary function tests (PFT’s), but even multiple or serial
assessment has been unsuccessful [3,10]. Categorizing
pulmonary phenotypes is much more challenging because
of the inability to use dichotomous determination and the
great variation in onset, evolution over time, and severity of
lung disease due to numerous intrinsic and extrinsic factors
[2,20,22–26]. Thus, when a new mutation is discovered in a
child with CF, it has been very difficult to prognosticate
regarding the risk of chronic lung disease. This gap in
knowledge of pulmonary phenotype categories, therefore,
limits efforts of both clinicians and researchers to under-
stand CF epidemiology and to predict prognosis [5,11]. We
have addressed this deficiency through a coordinated effort
between the Laboratoire Ge´ne´tique Mole´culaire in Brest,
France and the Wisconsin CF Neonatal Screening Project
with a primary goal of delineating genotype–pulmonary
phenotype relationships. In this report, we describe the
identification of two novel CF mutations, the case histories
of affected patients, and the development of a new,
quantitative method to categorize the associated pulmonary
phenotype based on comparison with F508del homozygotes
who were identified shortly after birth and evaluated
systematically over more than 12 years [1,15,16,20].2. Materials and methods
2.1. Patients, study design, and outcome measures
As described in detail elsewhere [27], the Wisconsin CF
Neonatal Screening Project is a randomized clinical trial
conducted by two Wisconsin CF centers (Madison and
Milwaukee) to assess the potential benefits and risks of
newborn screening for CF. According to a screening plan
and standardized Evaluation and Treatment Protocol [1]
developed in 1984, half of Wisconsin’s newborns from 15
April 1985 through 30 June 1994 were randomly assigned
to an early diagnosis group and screened with trypsinogen
or trypsinogen/DNA testing [15]. A group of 74 screened
patients was thus identified with a positive sweat test, and
38 of these included in this report were found to be F508del
homozygotes identified within the first 12 weeks of life; six
had MI at birth and all had PI by four years of age.
All patients, once diagnosed and enrolled, were placed on
the same Evaluation and Treatment Protocol developed bythe study group and approved by a Policy & Data Monitoring
Board [16]. Because the enrollment and evaluation phases of
the Wisconsin CF Neonatal Screening trial have continued
for approximately two decades, we have been very careful in
reaching decisions about changes in therapy. When new
pharmacologic agents emerged and were recommended for
CF patients such as antibiotics or respiratory inhalation
therapies such as DNase or tobramycin, the Policy and Data
Monitoring Board reviewed the information on benefits and
implications for study patients before reaching a conclusion.
When these ‘‘new’’ pharmaceuticals were incorporated into
the Protocol, they were used at the discretion of the treating
physician based on predetermined signs, symptoms, and
laboratory findings that would support such treatments. As
part of our monitoring protocol and data gathering exercises,
we have determined what treatments each patient received.
For drug therapy, including nutritional supplements, data
were collected from charts (anywhere noted in medical
records, i.e., prescription, doctors’ notes, phone notes, self
reports, etc). Then, we processed the information with a
database structure that had start and stop dates recorded
consistently, so that the interval of each treatment was known
precisely. In an analysis of data on outcomes related to
therapies, we have segregated the patients according to when
they were diagnosed, namely a chronologically early
subgroup, referred to herein as subgroup I, who were
diagnosed/enrolled between April 1985 and June 1990;
these patients were compared to subgroup II diagnosed/
enrolled between July 1990 and July 1994.
We prospectively followed and evaluated all patients
every six weeks for the first year of life and every three
months thereafter. They were managed with ‘‘standardized
care’’ [16] for the period of this study with monitoring/
advisory board input on implementation of new therapies
and monitoring their use. Enrolled patients were managed
quite successfully with aggressive nutritional support
[1,15,16], enabling us to focus on the pulmonary outcome
variables without malnutrition as a confounder [16,20]. As
shown in Table 1, there were 38 patients who were F508del
homozygotes and had PI. Also, there were 19 with PS and a
variety of other, presumably mild CFTR mutations that were
generally class IVor Valleles. These patients were generally
diagnosed as newborns by unequivocally positive sweat
tests (chloride levels above 60 mEq/l). Many of the PS
patients had CFTR mutations that remained unidentified
after initial, commercial mutation analyses and were studied
further at the Laboratorie de Ge´ne´tique Mole´culaire [27].
All patients consented to enrollment in this CF genotype
study and to DNA analysis directly or through their parents.
This study was approved by the Human Subjects Committee
at University of Wisconsin and the Research/Publications
Committee/Human Rights Board at Children’s Hospital of
Wisconsin at the Medical College of Wisconsin.
Pancreatic functional status was determined generally by
fat absorption studies [14] and by two other strategies
described elsewhere [15]: 1) following blood trypsinogen
Table 1
Summary of patient characteristics
Characteristics F508del
homozygote
group (n =38)
Pancreatic
sufficiency
groupa (n =19)
Sex Male 25 8
Female 13 11
Center Madison 21 12
Milwaukee 17 7
Group Screened 38 3
Control 0 14
Other 0 2
Meconium ileus Yes 6 0
No 32 19
Mean age at diagnosis
(weeks)TS.D.
7.15T2.4 193.1T192
Mean sweat
Cl mEq/lTS.D.
101.0T9.5 83.5T21.2
CXR scores at
diagnosis
WCXR 2.48T32b 4.68T71
BCXR 21.9T0.3 21.1T .48
Pulmonary function
at 8 years
FEV1 (%)c 97T4 104T2
FVC (%)c 103T3 103T2
FEV1/FVC% 0.92T0.03 0.98T .01
FEF25– 75% 99T11 104T5
a Mild pancreatic phenotype mutations include: R117H occurring with
F508del (n =5) and G542X (n =1); R117C with F508del (n =2); R347P
with F508del (n =1), R1066H (n =1) and 2184insA (n1), 2789+5G>A
with F508del (n =3); 327226A>G with F508del (n =1); 3849+10kbC>T
with F508del (n =1); L138ins with 327226A>G (n =1); R352Q with
F508del (n =1); and 1336K with F508del (n =1).
b MeanT standard error of the mean (SEM).
c Spirometry results as meanTSEM are % predicted values using the data
of Wang et al. [33].
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including beta plus gamma tocopherol levels which
decrease, along with alpha-tocopherol as PI develops
[15,28]. Pulmonary assessments [20,29–32] included symp-
toms of cough and wheezing, respiratory infections by
history, occurrence of pathogens on serial cultures, use of
antibiotics, quantitative chest radiology, and pulmonary
function tests (PFTs). Respiratory secretions from patients
were obtained at least every six months and at all ‘‘sick
visits’’ as described elsewhere [32,33]; they were then
cultured to identify Pseudomonas aeruginosa (Pa) and
Staphylococcus aureus (Sa), the two major respiratory
pathogens in CF. Spirometry to determine FEV1, FVC,
FEV1/FVC, and FEF25–75 values was obtained every six
months after approximately 4 years of age. The quality of
spirometry results was assessed by a new method known as
PASS [20], and only ‘‘acceptable’’ results were used in
statistical analyses. The % predicted values for %FEV1,
%FEV1/FVC, and %FEF25–75 were calculated from 6 years
of age based on equations by Wang et al. [33]. Chest
radiographs (postero–anterior and lateral views) were
obtained from 1985 through 2002 in each patient every
six months from diagnosis to age 4 years and annually
thereafter; they were scored by two raters using the
Wisconsin [30] and Brasfield [31] methods without knowl-
edge of patient identity. In the scoring sessions, repeatedchest radiographs were included to assess score reproduc-
ibility, as described previously [11,19]. A detailed descrip-
tion of quantitative chest radiography methods is provided
in a previous report [20], which demonstrates that a
threshold of potentially irreversible lung disease due to
bronchiectasis is likely when the Wisconsin score is 5 or
greater or the Brasfield score is 21 or less.
2.2. DNA extraction and CFTR mutation identification
DNA extractions of whole blood from CF patients were
systematically scanned using multiple gene scanning tech-
niques to determine the CFTR mutations and genotypes.
Whole blood was collected in an EDTA-containing vaccu-
tainer tube. Two milliliter aliquots of whole blood were used
to extract genomic DNA using the PUREGENE R* DNA
Isolation Kit manufactured by Gentra Systems, Minneap-
olis, MN. For DNA analysis, the extracts were first tested
with Elucigen 20, an Amplification Refractory Mutation
System (ARMS) kit made by AstraZenica Diagnostics. This
polymerase chain reaction (PCR)-gel electrophoresis based
technique tests for the 20 most common CF mutations in the
Caucasian population [18]. Addition of 2 Al of DNA to the
supplied reagent premix gave reproducible results. Follow-
ing ARMS testing, the yet untyped samples of DNA were
scanned as described previously [27] using denaturing
reverse-phase ion-pair high performance liquid chromatog-
raphy (D-HPLC) on a Transgenomics WAVE\ DNA
Fragment Analysis System. Primers for the DNA amplifi-
cation were designed using Primer Express software
(Applied Biosystems). After PCR was performed, the
scanned exons were chosen preferentially in terms of the
most frequent locations of CFTR point mutations [27]. The
results were interpreted independently by two researchers.
Following positive tests on either of the above two
techniques (ARMS or D-HPLC), the samples were se-
quenced on an Applied Biosystems ABI PRISM\ 310
DNA Sequencer to determine the exact base-pair mutation.
2.3. Statistical analyses
Clinical observations were documented prospectively
using forms created for the Evaluation and Treatment
Protocol of the Wisconsin CF Neonatal Screening Project
[16]. The clinical data, chest X-ray scores, pulmonary
function results, and culture information were entered in the
computer and managed using the ORACLE program of data
management. The longitudinal patterns of Wisconsin chest
X-Ray (WCXR) scores and Brasfield chest X-Ray scores
(BCXR) for homozygous F508del patients (n =38 patients,
totaling 259 longitudinal chest radiographs) were deter-
mined and the corresponding 95% confidence intervals were
calculated according to the method described in the next
paragraph. Thereafter, the longitudinal patterns of WCXR
and BCXR for the two patients with novel mutations (i.e.,
G1047R and 1525-2AYG) were superimposed on the
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Fig. 1. Wisconsin and Brasfield chest X-ray scores for F508del/F508del
group (n =38) and pancreatic sufficiency group (n =19). The bands show
the 95% confidence interval for each group, and the dashed lines indicate
the threshold value for probable radiographic irreversibility [20,32]. Group
comparisons using GEE models adjusting for center, gender, meconium
ileus status, and age revealed that the pancreatic sufficiency group was
significantly better than the F508dek/F508del group in WCXR [estimate
( p-value), 4.01 ( p < .001)] and BCXR [estimate ( p-value), 1.46
( p =.001)] scores. From ages 7 and 8 years, there were significant
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patients. The median times to WCXR5 or BCXR21
and the 95% confidence interval for this ‘‘point of no
return’’ [21], i.e., potentially irreversible lung disease due to
structural abnormalities such as bronchiectasis [20,32], were
also determined for the F508del homozygous patients.
The pulmonary outcome results for the 38 patients
homozygous for F508del were used to construct mean
estimates, standard errors of the means 95% confidence
intervals, and 95% one-sided prediction intervals for each
outcome as a function of age. The locally weighted
scatterplot smoothing technique (i.e., the LOESS function
in S-Plus) was used to fit the mean value as a function of
age. Standard errors were computed based on ignoring the
dependence between observations within the same individ-
uals. For comparative evaluation of individual patients,
prediction intervals were computed by multiplying these
standard errors by a constant which ensured that 5% of the
observations were outside of the interval. Thus, the
prediction intervals are adjusted for within-individual
correlation. Because observations from less severe pheno-
types should be lower than observations from more severe,
‘‘typical’’ phenotypes of F508del homozygotes, we only
used the side of the interval corresponding to less severe
values. For example, a lower bound is used for WCXR
scores [30] since lower scores reflect milder illness (0 is
normal and 100 is most severe). We note that prediction
intervals permit classification of individuals, whereas
confidence intervals only allow discrimination between
populations and not individuals.differences in WCXR and BCXR scores, respectively, between groups by
t test comparisons, i.e., at each age interval.3. Results
Analysis of data in the 38 patients who are homozygous
for F508del revealed chest radiographic scores that pro-
gressively worsened (Fig. 1) and spirometry results that
were generally normal (Table 1 and Fig. 2). At 8 years of
age, their PFT values were above the lower limit of normal.
The progressive development of lung disease, however, was
obvious by quantitative chest radiology. Table 1 and Fig. 1
show the typical severity pattern for F508del homozygotes
who have been maintained in a well nourished condition
after early diagnosis through neonatal screening [20].
Specifically, the data of Table 1 reveal that radiographic
evidence of lung disease was generally present at diagnosis,
and Fig. 1 (along with the other figures) depicts the
longitudinal pattern of CXR scores for the 38 F508del
homozygous patients, along with 95% confidence intervals.
All CF patients were fully genotyped and their mutations
confirmed by DNA sequencing. Two novel mutations for
North American CF patients were discovered during our
investigation process, namely G1047R (patient #1) and
1525-2AYG (patient #2). The clinical presentation and
history of the two patients with novel mutations may be
summarized as follows. Patient #1 is an 11-year-old whitefemale, identified through neonatal screening and a positive
sweat test at 5 weeks of age (chloride concentrations=78.8
and 92.9 mEq/l). She had PI by a 72-h fecal fat test and
showed cough at diagnosis by history and during the initial
physical exam. Respiratory secretions obtained at 6-month
intervals have shown that 50% of 24 cultures have been
positive for Pa. Her progression of lung disease is described
quantitatively in Fig. 3, which shows a linear pattern of
worsening with development of apparently irreversible lung
disease by 3 years of age, i.e., BCXR<21 and WCXR>5.
Pulmonary function tests at 8 and 11 years of age revealed
no abnormalities by spirometry. Patient #2 is a white male
with MI, requiring surgery on the first postnatal day, who
had a positive sweat test at 8 weeks of age. At 4 months of
age, he showed a prominent cough with tachypnea, an
abnormal chest radiograph (infiltrates in the right upper and
lower lobe regions), and Pa on culture of respiratory
secretions; however, all subsequent cultures for 18 years
were negative for Pa. Chest radiographic progression is
presented in Fig. 3, which shows that the patient’s CXR
scores passed the threshold of probable radiograph irrevers-
ibility before 2 years of age by the Wisconsin system. After
5 years, however, the severity slope attenuated. At 8 years of
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Fig. 3. Comparison of patients 1 and 2 with novel CFTR mutations with the
F508del/F508del and pancreatic sufficiency groups on the longitudinal
WCXR scores. The segments show the 95% patient-wise lower prediction
interval (calculated as described under Statistical analyses) and the dashed
line at WCXR=5 indicates the threshold for probable radiographic
irreversibility [20,32].
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Fig. 2. The % predicted FEV1 and % predicted FEF25 – 75 for F508del/
F508del group (n =38) and pancreatic sufficiency group (n =19). The bands
show the 95% confidence interval for each group. Group comparisons using
GEE models adjusting for center, gender, meconium ileus status, and age
revealed that the pancreatic sufficiency group was similar to the F508del/
F508del group in % predicted FEV1 [estimate ( p-value), 5.45 ( p =.12)]
and % predicted FEF25 – 75 [estimate ( p-value), 8.26 ( p =.27)]. There were
no significant differences in % predicted FEV1 and % predicted FEF25 – 75
between groups for any ages by t test comparisons.
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and FEV-1 (95%) but a moderately decreased FEF25–75 at
56%.
In order to classify the genotypes of these patients, we
examined the molecular nature and biochemical implica-
tions of the two novel mutations. G1047R describes a
guanine to cytosine base-pair substitution in the 1047th
codon which would lead to a missense mutation, changing
glycine to arginine. This mutation occurs at a natural splice
site of the CFTR gene at the end of exon 17a and likely
results in defective transcription of the gene with a resulting
absence of the CFTR protein. Therefore, this is a class I
mutation. The patient’s genotype of F508del/G1047R or
class II/I would suggest a ‘‘severe’’ phenotype as both
mutations lead to a loss of functional CFTR protein at the
apical cell membrane. This patient’s pancreatic phenotype is
consistent with this diagnosis, considering that she has PI.
The other novel mutation, 1525-2AYG, occurs in the
splice site region before exon 10 and consists of an adenine
to guanine base-pair substitution in the ninth intron, two
nucleotides before the 1525th nucleotide which begins at
exon 10. This mutation would also be designated a class I
mutation. Taking in to account the patient’s other mutation,
G551D, the genotype of G551D/1525-2AYG wouldtranslate to a class III/I genotype and a prediction of
‘‘severe’’ disease manifestations, which is consistent with
the MI presentation and early development of PI.
Categorization of these patients and others assessed
individually and/or in groups with regard to their pulmonary
phenotype was the primary goal of this study and four
options were examined using longitudinal data for this
determination: 1) clinical information on respiratory symp-
toms; 2) culture results, e.g., time of Pa appearance; 3)
pulmonary function testing data; and 4) WCXR and BCXR
scores assessed longitudinally in relationship to the thresh-
olds of probable irreversibility. Only the longitudinal
quantitative chest radiology approach was suitable as
described below because respiratory symptoms were non-
specific and intermittent, i.e., the stage of chronic productive
cough is difficult to identify in young children with CF;
culture results vary as illustrated by patient #2 who had Pa
transiently at 4 months of age and as documented previously
in many other Wisconsin patients [32,33]; and pulmonary
function test results were unrevealing despite chest radio-
graphic progression, i.e., they lack sufficient sensitivity.
Comparing the data of Fig. 3 with the longitudinal
patterns of chest X-ray scores in F508del homozygotes or
patients with PS reveals that both patient #1 and #2 show
the typical radiographic progression of CF lung disease. In
addition, their spirometry results are also similar to the
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Fig. 4. Categorization of ‘‘mild’’ mutation patients with the F508del/
F508del and pancreatic sufficiency groups based on the longitudinal
WCXR scores. The segments show the 95% patient-wise lower prediction
interval (calculated as described under Statistical analyses) and the dashed
line at WCXR=5 indicates the threshold for probable radiographic
irreversibility [20,32].
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fact, all longitudinal patterns of spirometry values for these
two patients between age 6 to 12 were similar to the
homozygous patients and reveal very mild pulmonary
dysfunction. More specifically, at age 8 years, patients #1
and #2 had %FEV-1 values of 95.7 and 106, respectively
compared to 98T4% for F508del homozygotes. Thus, these
two patients have chronic lung disease typical of F508del
homozygotes.
In addition, we studied a group of 19 patients with PS
who generally had class IV or V mutations as described in
Table 1. Their chest X-ray scores at diagnosis are also listed
in Table 1, while the scores over time are shown in Fig. 1.
The crossover age when WCXR 5 is older in the PS group
compared to F508del homozygotes ( p =.028). After ap-
proximately 6 years of age, both the WCXR and BCXR
scores diverge, and there is no overlap of 95% confidence
intervals. The suggestion in Fig. 1 that after 6 years of age
the typical and atypical (‘‘mild’’) patient subgroups can be
distinguished is supported by t test statistical comparisons at
7 ( p =0.059) and 8 ( p =.005) years of age. In addition, GEE
analysis revealed significant differences between the two
groups in WCXR ( p <0.001) and BCXR ( p =0.001) scores.
Pulmonary function data, however, are similar in comparing
the two groups. Specifically, as shown in Fig. 2, the %
predicted FEV-1 values and 95% confidence intervals
overlap until sometime after 10 years of age.
In contrast to patients #1 and #2, the longitudinal chest
radiography data on patients with PS are different from the
F508del homozygotes (e.g., R347P or 2789+5GYA as
shown in Fig. 4). In comparison with the longitudinal
progression of the F508del homozygote group, the F508del/
R347P child obviously shows an atypical pattern of
progression although she had slightly abnormal WCXR
and BCXR scores when diagnosed at 6 weeks with sweat
chloride values of 100 and 102 mEq/L. Her WCXR scores
after age 6 years are consistently below the 95% confidence
interval for F508del homozygotes, and she showed scores at
(7 years) or below (11 years) the 95% patient-wise
prediction interval. Clearly, her WCXR scores resemble
the PS group (Figs. 1 and 3). Similar to the other patients,
however, she had normal PFT’s at 8 years of age when she
showed Pa on culture of respiratory secretions. As Fig. 4
shows, the F508del/2789+56YA patient also resembles
the PS group graphically and has WCXR scores below the
prediction interval cutoff; however, again the PFT values
were normal.
In order to determine if there were differential treatment
effects in the diagnostic subgroups or the group of F508del
homozygotes compared to the PS group, we analyzed the
utilization data for three treatments, namely oral azithromy-
cin, inhaled DNase, and aerosolized tobramycin. Our results
showed that the F508del homozygote patients generally
received more of these treatments. For azithromycin, 21 of
38 (55%) of such patients received that antibiotic compared
to 7 of 19 (37%) of PS patients ( p =.19), for DNase, 15 of38 (39%) and 2 of 19 (11%) were treated ( p =.024), and for
aerosolized tobramycin, 19 of 38 (50%) of F508del
homozygote patients were treated compared to 2 of 19
(11%) of the PS group ( p =.004).
We also examined carefully the times of introduction of
new treatments in CF patients over a 20-year period. This
review demonstrated that aerosolized tobramycin use started
in January 1990, whereas aerosolized DNase was first used
in January 1994 and azithromycin was first prescribed in
January 1998. We used June 1990 as the midpoint for
diagnosis/enrollment and compared subgroup I (chronolog-
ically early) F508del homozygotes with subgroup II (those
diagnosed later). This revealed no significant change in
outcomes based on analysis of longitudinal chest X-ray data
using the GEE model. Specifically, we found an estimate
TSE of 1.05T1.97 ( p =.60) for WCXR and 0.70T .55
( p = .20) for Brasfield chest X-ray scores. Thus, we
conclude that thus far those treatments have not had
significant effects on grouped patients in this study,
although further analyses of such data are needed.4. Discussion
Mutations in the CFTR gene have been grouped into five
different classes according to the mechanism by which they
disrupt chloride channel function [2,4,10,11,19]. A variety
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phenotype in CF have demonstrated that some presumably
‘‘severe’’ mutations (based on the nature of the molecular
abnormality) are closely associated with pancreatic insuffi-
ciency or complications such as MI [5,7,10,11]. It has also
been suggested that a relationship between the presumed
severity of the mutations and the observed phenotype exists
not only for pancreatic status but also for the severity of the
respiratory system involvement [6,8,10]. However, in
contrast to dichotomous outcomes such as PI/PS or MI
(‘‘yes/no’’), bronchopulmonary disease seems to occur in an
evolving, variable pattern over time and is affected by many
intrinsic and extrinsic factors [2,20–26,28]. In a recent
study of 5 CFTR mutations frequently identified in Western
France, Dugue´pe´roux and De Braekeleer [10] reported
‘‘wide heterogeneity’’ and an inability of PFTs to distinguish
patients and subgroups.
Encouraged by results demonstrating greater sensitivity
of quantitative chest radiography compared to PFTs [20,26]
in evaluation of Wisconsin children with CF, we have
proceeded with a comprehensive analysis of all apparent
options for pulmonary phenotype delineation of patients
genotyped with the assistance of D-HPLC. The discovery of
two novel mutations was an unexpected outcome of our
overall goal to provide a better understanding of the
correlation between CF genotype and a given patient’s
phenotype. The two novel mutations (G1047R and 1525-
2AYG) are named following accepted recommendations
[34]. Both are class I mutations and the resulting genotypes
are II/I (patient #1) and III/I (patient #2). Thus, ‘‘severe’’
disease would be expected according to customary pre-
dictions regarding PI and anticipated lung disease. Spirom-
etry results, however, demonstrated relatively mild
pulmonary dysfunction for both patients with novel
mutations and for most of the patients reported herein
(Table 1). Although the MI, PI, and respiratory culture
positive at 4 months for Pa suggested during early
childhood that patient #2 would have ‘‘severe’’ disease, he
has actually been less severely affected by lung disease than
expected. This case is an example which is challenging to
the phenotype-reflecting–genotype theory as it seems to
refute the concept that disease manifestations mirror a CF
patient’s genotype. It is likely that this patient has benefited
from therapeutic advances, or perhaps there are other
genetic [e.g., CF gene modifiers [9,10,11,35]] or environ-
mental [e.g., avoidance of Pa exposure [25,26,33]] factors
that have attenuated the progression of his disease. Thus, it
is clear that patient #2 illustrates the difficulties associated
with attempting to prognosticate in children with CF using
genotype as a predictive factor without an ability to
incorporate extrinsic variables.
Our epidemiologic studies, however, especially observa-
tions reported herein on F508del homozygotes, permit
description of a typical or ‘‘classic’’ CF pulmonary
phenotype based on using quantitative chest radiology
[20,30]. A typical pulmonary phenotype is defined hereinas early onset of lung disease, progressive worsening of
CXR scores, and irreversible structural abnormalities (e.g.,
bronchiectasis) in early childhood (by 2–3 years of age), as
determined radiographically. We characterize early onset to
be less than 12 months of age, although we and others [8]
often see lung disease beginning at 1 to 3 months of age. An
atypical pulmonary phenotype is quantitatively milder than
typical due to slower progression of lung disease, as
illustrated by individual or grouped patients with PS. They
can be recognized statistically after 6 years of age with the
quantitative radiology method described herein. We believe
that this method can be generally applied in other CF centers
and offers advantages over chest CT scans which cannot be
used serially. On the other hand, it remains to be determined
if further research will reveal the typical and atypical
pulmonary outcomes reported herein. The patients of the
Wisconsin CF Neonatal Screening Project differ from others
in their age of diagnosis, usual lack of chronic malnutrition
and low rate of hospitalization [20].
The question has arisen as to the effect of new therapies
on CF patients studied for a long period such as the 20 year
interval thus far of the Wisconsin CF Neonatal Screening
Project. Therapies of particular interest are those that have
been shown to be effective for chronic lung disease. Thus,
we investigated oral azithromycin and inhaled DNase or
tobramycin. It was important to determine that the patients
with PS used less of these treatments than the F508del
homozygote group. Although this is not surprising, it is
consistent with less lung disease. On the other hand, we
were surprised to find that patients grouped before and after
June 1990 diagnosis/enrollment are not different thus far in
this radiographic progression of lung disease.
In order to determine when and if longitudinal
quantitative radiology would apply to groups of patients
with potentially ‘‘mild’’ pulmonary phenotypes, as well as
individual patients, we performed the comparative analyses
presented in Figs. 1 and 4. The group of 19 patients with
minor mutations and PS afforded us the opportunity to
determine an anticipated age of divergence if this method
is applicable. The data clearly show that after 6 years of
age the typical and atypical pulmonary phenotypes can be
distinguished. To our knowledge this is the youngest age
that PS patients have been distinguished from those with
PI. This is well before pulmonary function testing by
spirometry reveals a difference, as reported by Corey et al.
[36].
The application of genotype information to predicting
pulmonary prognosis and informing genetic counseling has
been controversial [5,9,11]. In fact, the Cystic Fibrosis
Genotype–Phenotype Consortium stated that ‘‘the only
prognostic value of genotypic information is for the
prediction of pancreatic status’’ [5]. However, previous
investigations have been limited to cross sectional studies
using either pulmonary function data or remote surrogates
such as pseudomonas infections or hospitalizations
[5,6,8,11]. Thus, methodological limitations have contrib-
A.T. Braun et al. / Journal of Cystic Fibrosis 5 (2006) 33–4140uted to this impression, along with the conceptual issue that
CF genotype only creates lung disease predisposition and
the timing of susceptibility depends largely on environmen-
tal factors. However, we believe that genetic counseling and
prognostication might be improved significantly by deter-
mining a patient’s two CF mutations using gene scanning
methods such as D-HPLC [27], classifying the genotype,
and determining the pulmonary phenotype by longitudinal
quantitative chest radiology. CFTR mutation analysis gives
insight into precise molecular abnormalities, a classification
of the genotype and categorization of phenotype. This
should allow a given patient’s long term outlook to be more
clearly defined, particularly as more information emerges
from epidemiologic studies of extrinsic factors such as
mucoid Pa [37]. Moreover, studies of genotyped patients
might provide new indications for therapeutic modalities
that may be more beneficial in certain genetic subtypes. In
epidemiologic studies, the method of quantitative chest
radiology, using either the Wisconsin system or another
method [31,38], can be applied retrospectively (using stored
chest films) or prospectively. This strategy is readily
applicable to young children with CF and is superior to
pediatric pulmonary function testing, which simply doesn’t
provide the sensitive longitudinal evaluations needed [20]
and has been disappointing in studies related to genotype
[5,11].
In conclusion, we believe that CF genotype classification
and predicted pulmonary phenotype category by serial
quantitative chest radiology represent a significant advance.
Although more study of larger CF patient groups is needed,
we suggest that with routine early diagnosis through CF
neonatal screening and prospective, serial chest images, the
classification of genotypes and categorization of both
pancreatic and pulmonary phenotypes will become more
common and valuable in the future.Acknowledgments
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